Synthetic biology sells picks and shovels for the $4 trillion bioeconomy, and Codon Capital sees this opportunity. Mitchell Mutz—the accomplished venture investor, biotech serial entrepreneur, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results